newsfilter
← Latest News
Business Wire·

Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma

Protocol amendment to change SIGMA from a Phase 2 to a Phase 3 study now complete The currently enrolling SIGMA trial will now include patients with grade 2 astrocytoma with high-risk features in the maintenance